Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc is positioned favorably due to its innovative pipeline, highlighted by GRI-0621 and GRI-0803, which presents strong potential for addressing serious autoimmune and inflammatory disorders. Recent clinical data, including positive interim results related to lung function and biomarker impact, underscore the efficacy and safety of GRI Bio's therapies, suggesting promising future outcomes. The company's valuation remains attractive, with significant upside potential reflected in the net present value analysis, indicating that the current share price does not fully reflect the expected future growth of the company's pipeline.

Bears say

GRI Bio Inc experienced significant financial losses, posting a net loss of $3.4 million for the reported period, resulting in an earnings per share (EPS) of $(1.28), which was below both the analyst estimates of $(1.11) and consensus expectations of $(0.93). Additionally, the company recorded another considerable net loss of $3.9 million with an EPS of $(7.72), which again exceeded the projections set by analysts and the market consensus. The financial outlook is further complicated by a range of risks, including concerns over liquidity, the efficacy and safety of product candidates in clinical trials, and challenges associated with regulatory approvals, commercialization, and market competition.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.